RxSight, Inc.
RXST- Exchange
- Nasdaq
- Industry
- Ophthalmic Goods
- SEC CIK
- 0001111485
In the last 90 days, RxSight, Inc. insiders filed 0 open-market purchases and 4 sales; 151 institutions reported holding it in 13F filings for Q2 2026, worth $199.8M in total; no superinvestor holds it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Nov 5, 2026, 12:11 AM ET
Revenue flow, FY2025
Where the revenue went in FY2025, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.
Net loss for FY2025: $38.9M (29.0% of revenue).
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 12, 2026 | Jan 13, 2025 | Jan 8, 2024 | Jan 9, 2023 | Jan 10, 2022 |
| Revenue | $134.5M | $139.9M | $89.1M | $49.0M | $22.6M |
| Cost of revenue | $31.5M | $41.0M | $35.3M | $27.7M | $18.1M |
| Gross profit | $103.0M | $98.9M | $53.8M | $21.3M | $4.52M |
| Operating expenses | $151.2M | $135.8M | $103.8M | $84.6M | $57.3M |
| Research and development | $38.5M | $34.4M | $29.1M | $26.0M | $24.5M |
| Selling, general and administrative | $112.7M | $101.4M | $74.8M | $58.7M | $32.8M |
| Operating income | -$48.2M | -$36.9M | -$50.1M | -$63.3M | -$52.8M |
| Interest expense | $19.0K | $21.0K | $3.31M | $4.95M | $3.68M |
| Income tax | $66.0K | $50.0K | $20.0K | $9.00K | $8.00K |
| Net income | -$38.9M | -$27.5M | -$48.6M | -$66.8M | -$48.7M |
| EPS, basic | $-0.95 | $-0.71 | $-1.41 | $-2.41 | $-3.57 |
| EPS, diluted | $-0.95 | $-0.71 | $-1.41 | $-2.41 | $-3.57 |
| Weighted shares, basic | 40.9M | 38.9M | 34.5M | 27.7M | 13.6M |
| Weighted shares, diluted | 40.9M | 38.9M | 34.5M | 27.7M | 13.6M |
| Margins and growth | |||||
| Gross margin | 76.6% | 70.7% | 60.4% | 43.5% | 20.0% |
| Operating margin | -35.8% | -26.3% | -56.2% | -129.2% | -233.6% |
| Net margin | -29.0% | -19.6% | -54.6% | -136.2% | -215.5% |
| Revenue growth, year over year | −3.9% | +57.1% | +81.8% | +116.9% | – |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 12, 2026 | Jan 13, 2025 | Jan 8, 2024 | Jan 9, 2023 | Jan 10, 2022 |
| Cash and equivalents | $19.9M | $16.7M | $9.69M | $11.8M | $24.4M |
| Short-term investments | $208.2M | $220.5M | $117.5M | $94.0M | $135.0M |
| Accounts receivable | $23.4M | $30.1M | $20.3M | $11.0M | $4.86M |
| Inventory | $31.6M | $22.0M | $17.4M | $14.8M | $8.03M |
| Total current assets | $287.5M | $293.8M | $168.4M | $134.6M | $176.3M |
| Property, plant and equipment | $13.1M | $12.4M | $10.8M | $10.1M | $11.2M |
| Total assets | $311.8M | $318.6M | $182.6M | $150.2M | $192.7M |
| Accounts payable | $5.30M | $4.54M | $3.86M | $2.60M | $1.69M |
| Total current liabilities | $26.3M | $25.9M | $20.9M | $17.2M | $11.1M |
| Long-term debt | – | – | $0 | $40.2M | $39.8M |
| Total liabilities | $36.1M | $37.3M | $22.2M | $60.3M | $54.5M |
| Shareholders' equity | $275.7M | $281.2M | $160.4M | $89.9M | $138.2M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 12, 2026 | Jan 13, 2025 | Jan 8, 2024 | Jan 9, 2023 | Jan 10, 2022 |
| Operating cash flow | -$15.5M | -$16.9M | -$41.6M | -$58.9M | -$44.7M |
| Capital expenditures | $3.83M | $5.44M | $4.81M | $2.39M | $1.94M |
| Free cash flow | -$19.3M | -$22.4M | -$46.4M | -$61.2M | -$46.6M |
| Depreciation and amortization | $3.27M | $3.58M | $4.08M | $3.88M | $3.98M |
| Stock-based compensation | $31.6M | $24.6M | $15.7M | $11.4M | $7.58M |
| Investing cash flow | $16.9M | -$99.3M | -$22.1M | $40.0M | -$81.9M |
| Financing cash flow | $1.86M | $123.3M | $61.5M | $6.33M | $137.3M |
| Net change in cash | $3.24M | $7.05M | -$2.19M | -$12.6M | $10.7M |
| Ratio | |||||
| Stock-based compensation, % of revenue | 23.5% | 17.6% | 17.7% | 23.3% | 33.5% |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.